Why the study?
Is measurement of CK-MB mass concentration better than catalytic activity for infarct sizing in patients with acute myocardial infarction?
Is measurement of CK-MB mass concentration better than catalytic activity for infarct sizing in patients with acute myocardial infarction?
CK-MB mass concentration measurement is superior to catalytic activity measurement for infarct sizing after acute myocardial infarction.
Answers are grounded in this paper and cite their sources.
CK-MB mass concentration may aid infarct sizing; leaves open whether it should replace activity assays in practice.
We compared three current methods (immunoinhibition, "Isomune-CK" immunoprecipitation, and the Tandem-E CKMB II immunoenzymometric assay) for determination of creatine kinase (CK; EC 2.7.3.2) isoenzyme MB in serum. Although results inter-correlated well, the immunoinhibition assay gave higher activity values. Atypical CK forms did not interfere with the immunoprecipitation and immunoenzymometric methods. In acute myocardial infarction the catalytic properties of CK decreased with the enzyme's age, as reflected by a steady increase in activation energy of the catalyzed reaction. In septicemia patients with very low CK and CK-MB catalytic activity, mean CK-MB mass concentration exceeded the upper reference limit, suggesting an increased rate of loss of activity concentration in these patients' sera. Because of the assay's lesser susceptibility to conformational changes at the active site of the enzyme, we suggest that measurement of CK-MB mass concentration is better suited for infarct sizing than measurement of catalytic activity.
No takes yet. Share an insight, caveat, or question.
Delanghe et al. (1990) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: